JP2022538300A5 - - Google Patents
Info
- Publication number
- JP2022538300A5 JP2022538300A5 JP2021577425A JP2021577425A JP2022538300A5 JP 2022538300 A5 JP2022538300 A5 JP 2022538300A5 JP 2021577425 A JP2021577425 A JP 2021577425A JP 2021577425 A JP2021577425 A JP 2021577425A JP 2022538300 A5 JP2022538300 A5 JP 2022538300A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025010564A JP2025061798A (ja) | 2019-06-27 | 2025-01-24 | Ｃｎｓ障害を治療するための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867662P | 2019-06-27 | 2019-06-27 | |
| US201962867646P | 2019-06-27 | 2019-06-27 | |
| US201962867657P | 2019-06-27 | 2019-06-27 | |
| US62/867,646 | 2019-06-27 | ||
| US62/867,662 | 2019-06-27 | ||
| US62/867,657 | 2019-06-27 | ||
| PCT/US2020/040119 WO2020264495A1 (en) | 2019-06-27 | 2020-06-29 | Compositions and methods for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010564A Division JP2025061798A (ja) | 2019-06-27 | 2025-01-24 | Ｃｎｓ障害を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538300A JP2022538300A (ja) | 2022-09-01 |
| JP2022538300A5 true JP2022538300A5 (https=) | 2023-07-07 |
| JP7754725B2 JP7754725B2 (ja) | 2025-10-15 |
Family
ID=71670443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577425A Active JP7754725B2 (ja) | 2019-06-27 | 2020-06-29 | Ｃｎｓ障害を治療するための組成物及び方法 |
| JP2025010564A Pending JP2025061798A (ja) | 2019-06-27 | 2025-01-24 | Ｃｎｓ障害を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010564A Pending JP2025061798A (ja) | 2019-06-27 | 2025-01-24 | Ｃｎｓ障害を治療するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230085354A1 (https=) |
| EP (1) | EP3990467A1 (https=) |
| JP (2) | JP7754725B2 (https=) |
| KR (1) | KR20220038681A (https=) |
| CN (1) | CN114787174A (https=) |
| AU (1) | AU2020304673A1 (https=) |
| BR (1) | BR112021026447A2 (https=) |
| CA (1) | CA3144701A1 (https=) |
| IL (1) | IL289173A (https=) |
| MX (2) | MX2021015848A (https=) |
| TW (1) | TW202114696A (https=) |
| WO (1) | WO2020264495A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| BR112020012761A2 (pt) | 2017-12-22 | 2021-02-17 | Sage Therapeutics, Inc. | composições e métodos para o tratamento de distúrbios do snc |
| EP4321519B1 (en) * | 2018-10-12 | 2026-04-08 | Sage Therapeutics, LLC | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| CN115651054B (zh) * | 2019-01-08 | 2024-06-21 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| CA3143509A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2022246634A1 (en) * | 2021-05-25 | 2022-12-01 | Zhejiang Jiachi Development Pharmaceuticals Ltd. | Compositions for treating insomnia and uses thereof |
| CN114409717B (zh) * | 2021-12-17 | 2023-03-17 | 湖南科益新生物医药有限公司 | 替勃龙中间体醚化物和替勃龙的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES432106A1 (es) * | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| DE2445161A1 (de) * | 1974-09-19 | 1976-04-01 | Schering Ag | D-homo-20-ketopregnane ii |
| DE2360443A1 (de) * | 1973-11-30 | 1975-06-05 | Schering Ag | D-homo-20-ketopregnane |
| IL48628A0 (en) * | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) * | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) * | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| GB1581235A (en) * | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| BR112020012761A2 (pt) * | 2017-12-22 | 2021-02-17 | Sage Therapeutics, Inc. | composições e métodos para o tratamento de distúrbios do snc |
| EP3750909B1 (en) * | 2018-02-11 | 2025-03-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| CN115651054B (zh) * | 2019-01-08 | 2024-06-21 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
-
2020
- 2020-06-29 JP JP2021577425A patent/JP7754725B2/ja active Active
- 2020-06-29 MX MX2021015848A patent/MX2021015848A/es unknown
- 2020-06-29 US US17/620,303 patent/US20230085354A1/en active Pending
- 2020-06-29 KR KR1020227002449A patent/KR20220038681A/ko active Pending
- 2020-06-29 WO PCT/US2020/040119 patent/WO2020264495A1/en not_active Ceased
- 2020-06-29 AU AU2020304673A patent/AU2020304673A1/en active Pending
- 2020-06-29 BR BR112021026447A patent/BR112021026447A2/pt unknown
- 2020-06-29 EP EP20743025.7A patent/EP3990467A1/en active Pending
- 2020-06-29 CA CA3144701A patent/CA3144701A1/en active Pending
- 2020-06-29 TW TW109121937A patent/TW202114696A/zh unknown
- 2020-06-29 CN CN202080059464.3A patent/CN114787174A/zh active Pending
-
2021
- 2021-12-16 MX MX2025008327A patent/MX2025008327A/es unknown
- 2021-12-20 IL IL289173A patent/IL289173A/en unknown
-
2025
- 2025-01-24 JP JP2025010564A patent/JP2025061798A/ja active Pending
- 2025-06-11 US US19/234,399 patent/US20260098053A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538300A5 (https=) | ||
| JP2022538301A5 (https=) | ||
| JP2023537632A5 (https=) | ||
| JP2022538299A5 (https=) | ||
| JP2022510683A5 (https=) | ||
| JP2023119042A5 (https=) | ||
| JP2018502891A5 (https=) | ||
| JP2022516469A5 (https=) | ||
| JP2023540350A5 (https=) | ||
| JP2012515166A5 (https=) | ||
| JP2022514385A5 (https=) | ||
| JP2022511477A5 (https=) | ||
| JP2022504607A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JP2023531517A5 (https=) | ||
| RU2020131091A (ru) | Композиции и способы для лечения расстройств цнс | |
| JP2018505898A5 (https=) | ||
| RU2005117789A (ru) | Производные 4,5-диарилтиазола в качестве лигандов св-1 | |
| JP2022534702A5 (https=) | ||
| RU2219179C2 (ru) | Азациклические соединения, фармацевтические композиции | |
| JP2010504280A5 (https=) | ||
| JP2008504266A5 (https=) | ||
| JP2006505543A5 (https=) | ||
| JP2024541910A5 (https=) | ||
| JP2025505994A5 (https=) |